Localization of protein gene product 9.5 immunoreactivity in derivatives of the human Wolffian duct and in prostate cancer

Citation
G. Aumuller et al., Localization of protein gene product 9.5 immunoreactivity in derivatives of the human Wolffian duct and in prostate cancer, PROSTATE, 38(4), 1999, pp. 261-267
Citations number
17
Categorie Soggetti
Urology & Nephrology","da verificare
Journal title
PROSTATE
ISSN journal
02704137 → ACNP
Volume
38
Issue
4
Year of publication
1999
Pages
261 - 267
Database
ISI
SICI code
0270-4137(19990301)38:4<261:LOPGP9>2.0.ZU;2-K
Abstract
BACKGROUND. Protein gene product 9.5 (PGP 9.5) has been considered to be a neuronal marker, but it is also present in extraneuronal tissues, e.g., the human mammary gland and rat epididymis. Its presence and distribution in t he developing and adult male human genital tract have been unknown. METHODS. Immunohistochemical reactions were performed on human embryonic an d postnatal specimens of the male genital tract, using commercial monoclona l and polyclonal antibodies. RESULTS. PGP 9.5 immunoreactivity was found in the Wolffian duct of human e mbryos (55-85 mm crown-rump length). Strong reactivity was observed in meso nephric tubular cells and at the apical rim of Wolffian duct cells. Owing t o their PGP 9.5 immunoreactivity, these cells could also be identified on t he surface of the embryonic verumontanum, extending from the orifices of th e Wolffian duct to a small stretch of the urogenital sinus. There they cont rasted sharply against non-Wolffian cells. Ln the adult human genital tract , PGP 9.5 immunoreactive material was present in the supranuclear portion o f some epithelial cells of the epididymal efferent ductules, in isolated ce lls of the ejaculatory ducts, and in prostate cancer specimens. In the ejac ulatory ducts, the PGP 9.5-immunoreactive cells were free of immunoreactivi ty for semenogelin, the major secretory product of the ejaculatory-vesicula r-ampullary complex, and they also lacked chromogranin A-immunoreactivity. In prostate cancer specimens, PGP 9.5 immunoreactivity was never observed i n secretory cells (immunoreactive for prostate-specific antigen), but was r estricted to neuroendocrine cells, where it occurred either alone or coexpr essed with chromogranin A-immunoreactivity. CONCLUSIONS. PGP 9.5-immunoreactivity is prenatally distributed in the Wolf fian duct and its derivations; postnatally, it is restricted to a few cells derived from the initial and terminal segment of the Wolffian duct, and to neuroendocrine cells in prostate cancer specimens. (C) 1999 Wiley-Liss, In c.